Compare AEO & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEO | EWTX |
|---|---|---|
| Founded | 1977 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 1994 | 2021 |
| Metric | AEO | EWTX |
|---|---|---|
| Price | $26.97 | $24.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $20.70 | ★ $35.89 |
| AVG Volume (30 Days) | ★ 9.7M | 1.2M |
| Earning Date | 12-02-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $5,340,609,000.00 | N/A |
| Revenue This Year | $1.26 | N/A |
| Revenue Next Year | $1.78 | N/A |
| P/E Ratio | $22.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.27 | $10.60 |
| 52 Week High | $25.57 | $35.50 |
| Indicator | AEO | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 81.03 | 62.67 |
| Support Level | $22.12 | $22.77 |
| Resistance Level | $24.66 | $25.00 |
| Average True Range (ATR) | 1.09 | 1.33 |
| MACD | 0.45 | -0.28 |
| Stochastic Oscillator | 99.76 | 42.74 |
American Eagle Outfitters Inc is a specialty retailer. The company is engaged in the retail of apparel and accessories with company stores in the United States, Canada, Mexico, and Hong Kong. The Company leases all store premises, regional distribution facilities, some of its office space, and certain information technology and office equipment. American Eagle also has its online business. It operates in two segments: American Eagle and Aerie. The majority of its revenue comes from its primary brand, American Eagle, which offers an assortment of specialty apparel, accessories, and personal care products for women and men. Geographically, it generates the majority of its revenue from the United States.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.